UBS raised the firm’s price target on AnaptysBio (ANAB) to $20 from $18 and keeps a Neutral rating on the shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANAB:
- AnaptysBio’s Promising Pipeline and Financial Stability Justify Buy Rating
- AnaptysBio price target raised to $45 from $40 at Wedbush
- Promising Clinical Trial Results and Strategic Growth Potential Drive Buy Rating for AnaptysBio
- AnaptysBio Reports Q2 2025 Financial Results and Updates
- AnaptysBio: Promising Pipeline and Strategic Developments Justify Buy Rating